Stockreport

SAB Biotherapeutics Provides SAB-142 Trial Update [Yahoo! Finance]

SAB Biotherapeutics, Inc.  (SABS) 
PDF biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type [Read more]